Taysha Gene Therapies, Inc. Other Noncash Income (Expense)
Taysha Gene Therapies, Inc. (TSHA) reported Other Noncash Income (Expense) of -$123.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-11
- Taysha Gene Therapies, Inc. other noncash income (expense) for the quarter ending 2026-06-30 was -$96.00K.
- Taysha Gene Therapies, Inc. other noncash income (expense) for the quarter ending 2026-03-31 was -$27.00K, a 640.00% decline year-over-year.
- Taysha Gene Therapies, Inc. other noncash income (expense) for the quarter ending 2025-12-31 was -$32.00K.
- Taysha Gene Therapies, Inc. other noncash income (expense) for the quarter ending 2025-09-30 was -$28.00K.
- Taysha Gene Therapies, Inc. other noncash income (expense) for fiscal 2025 was -$296.00K.
- Taysha Gene Therapies, Inc. other noncash income (expense) for fiscal 2024 was -$750.00K.
- Taysha Gene Therapies, Inc. other noncash income (expense) for fiscal 2023 was -$741.00K.
- Taysha Gene Therapies, Inc. other noncash income (expense) for fiscal 2022 was -$906.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 9 month as first filed | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$96.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$123.00K 10-Q · filed 2026-08-11 | -$155.00K derived: sum of 3 quarters · filed 2026-08-11 | -$183.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$27.00K 10-Q · filed 2026-05-06 | -$59.00K derived: sum of 2 quarters · filed 2026-05-06 | -$87.00K derived: sum of 3 quarters · filed 2026-05-06 | -$328.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$60.00K derived: sum of 2 quarters · filed 2026-03-19 | -$301.00K derived: sum of 3 quarters · filed 2026-08-11 | -$296.00K 10-K · filed 2026-03-19 | |
| 2025-09-30 | -$28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$269.00K derived: sum of 2 quarters · filed 2026-08-11 | -$264.00K 10-Q · filed 2025-11-04 | -$336.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | -$241.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$236.00K 10-Q · filed 2026-08-11 | -$308.00K derived: sum of 3 quarters · filed 2026-08-11 | -$985.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $5.00K 10-Q · filed 2026-05-06 | -$67.00K derived: sum of 2 quarters · filed 2026-05-06 | -$744.00K derived: sum of 3 quarters · filed 2026-05-06 | -$718.00K derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | -$72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$749.00K derived: sum of 2 quarters · filed 2026-03-19 | -$723.00K derived: sum of 3 quarters · filed 2026-03-19 | -$750.00K 10-K · filed 2026-03-19 | |
| 2024-09-30 | -$677.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$651.00K derived: sum of 2 quarters · filed 2025-11-04 | -$678.00K 10-Q · filed 2025-11-04 | -$838.00K derived: sum of 4 quarters · filed 2025-11-04 | |
| 2024-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.00K 10-Q · filed 2025-08-12 | -$161.00K derived: sum of 3 quarters · filed 2025-08-12 | -$355.00K derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$27.00K 10-Q · filed 2025-05-15 | -$187.00K derived: sum of 2 quarters · filed 2025-05-15 | -$381.00K derived: sum of 3 quarters · filed 2025-05-15 | -$640.00K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$160.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$354.00K derived: sum of 2 quarters · filed 2025-02-26 | -$613.00K derived: sum of 3 quarters · filed 2025-02-26 | -$741.00K 10-K · filed 2025-02-26 | |
| 2023-09-30 | -$194.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$453.00K derived: sum of 2 quarters · filed 2024-11-13 | -$581.00K 10-Q · filed 2024-11-13 | -$871.00K derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$259.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$387.00K 10-Q · filed 2024-08-12 | -$677.00K derived: sum of 3 quarters · filed 2024-08-12 | -$906.00K derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | -$128.00K 10-Q · filed 2024-05-14 | -$418.00K derived: sum of 2 quarters · filed 2024-05-14 | -$647.00K derived: sum of 3 quarters · filed 2024-05-14 | -$840.00K derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$290.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$519.00K derived: sum of 2 quarters · filed 2024-03-19 | -$712.00K derived: sum of 3 quarters · filed 2024-03-19 | -$906.00K 10-K · filed 2024-03-19 | |
| 2022-09-30 | -$229.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$422.00K derived: sum of 2 quarters · filed 2023-11-14 | -$616.00K 10-Q · filed 2023-11-14 | -$554.00K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$193.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$387.00K 10-Q · filed 2023-08-14 | -$325.00K derived: sum of 3 quarters · filed 2023-08-14 | -$581.00K derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$194.00K 10-Q · filed 2023-05-11 | -$132.00K derived: sum of 2 quarters · filed 2023-05-11 | -$388.00K derived: sum of 3 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$194.00K derived: sum of 2 quarters · filed 2023-03-28 | -$388.00K 10-K · filed 2023-03-28 | ||
| 2021-09-30 | -$256.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$450.00K 10-Q · filed 2022-11-08 | -$93.00K 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | -$194.00K 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |